These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38304857)
61. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Garrido P; Paz-Ares L; Majem M; Morán T; Trigo JM; Bosch-Barrera J; Garcίa-Campelo R; González-Larriba JL; Sánchez-Torres JM; Isla D; Viñolas N; Camps C; Insa A; Juan Ó; Massuti B; Paredes A; Artal Á; López-Brea M; Palacios J; Felip E Cancer Med; 2021 Sep; 10(17):5878-5888. PubMed ID: 34296539 [TBL] [Abstract][Full Text] [Related]
62. Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR. Wu SG; Gow CH; Chen YL; Liu YN; Tsai MF; Shih JY Int J Cancer; 2023 Jul; 153(2):352-363. PubMed ID: 36912241 [TBL] [Abstract][Full Text] [Related]
63. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. Wang C; Zhao K; Hu S; Dong W; Gong Y; Li M; Xie C Lung Cancer; 2022 Oct; 172():86-93. PubMed ID: 36027855 [TBL] [Abstract][Full Text] [Related]
64. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T; Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371 [TBL] [Abstract][Full Text] [Related]
65. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Chung KP; Wu SG; Wu JY; Yang JC; Yu CJ; Wei PF; Shih JY; Yang PC Clin Cancer Res; 2012 Jun; 18(12):3470-7. PubMed ID: 22510346 [TBL] [Abstract][Full Text] [Related]
66. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C Ann Oncol; 2015 Sep; 26(9):1877-1883. PubMed ID: 26141208 [TBL] [Abstract][Full Text] [Related]
67. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. Chamorro DF; Cardona AF; Rodríguez J; Ruiz-Patiño A; Arrieta O; Moreno-Pérez DA; Rojas L; Zatarain-Barrón ZL; Ardila DV; Viola L; Recondo G; Blaquier JB; Martín C; Raez L; Samtani S; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Archila P; Bermudez M; Gamez T; Russo A; Malapelle U; de Miguel Perez D; de Lima VCC; Freitas H; Saldahna E; Rolfo C; Rosell R; Target Oncol; 2023 May; 18(3):425-440. PubMed ID: 37017806 [TBL] [Abstract][Full Text] [Related]
68. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627 [TBL] [Abstract][Full Text] [Related]
69. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC; Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444 [TBL] [Abstract][Full Text] [Related]
70. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S; Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016 [TBL] [Abstract][Full Text] [Related]
71. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Chen G; Feng J; Zhou C; Wu YL; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu CP; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C Ann Oncol; 2013 Jun; 24(6):1615-22. PubMed ID: 23456778 [TBL] [Abstract][Full Text] [Related]
72. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). Zhao H; Yao W; Min X; Gu K; Yu G; Zhang Z; Cui J; Miao L; Zhang L; Yuan X; Fang Y; Fu X; Hu C; Zhu X; Fan Y; Yu Q; Wu G; Jiang O; Du X; Liu J; Gu W; Hou Z; Wang Q; Zheng R; Zhou X; Zhang L J Thorac Oncol; 2021 Sep; 16(9):1533-1546. PubMed ID: 34033974 [TBL] [Abstract][Full Text] [Related]
73. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Cho BC; Chewaskulyong B; Lee KH; Dechaphunkul A; Sriuranpong V; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cheng Y; Cho EK; Voon PJ; Lee JS; Mann H; Saggese M; Reungwetwattana T; Ramalingam SS; Ohe Y J Thorac Oncol; 2019 Jan; 14(1):99-106. PubMed ID: 30240852 [TBL] [Abstract][Full Text] [Related]
74. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Zhou Q; Xu CR; Cheng Y; Liu YP; Chen GY; Cui JW; Yang N; Song Y; Li XL; Lu S; Zhou JY; Ma ZY; Yu SY; Huang C; Shu YQ; Wang Z; Yang JJ; Tu HY; Zhong WZ; Wu YL Cancer Cell; 2021 Sep; 39(9):1279-1291.e3. PubMed ID: 34388377 [TBL] [Abstract][Full Text] [Related]
75. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107 [TBL] [Abstract][Full Text] [Related]
76. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024 [TBL] [Abstract][Full Text] [Related]
77. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384 [TBL] [Abstract][Full Text] [Related]
78. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T; Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727 [TBL] [Abstract][Full Text] [Related]
79. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. Piccirillo MC; Bonanno L; Garassino MC; Esposito G; Dazzi C; Cavanna L; Burgio MA; Rosetti F; Rizzato S; Morgillo F; Cinieri S; Veccia A; Papi M; Tonini G; Gebbia V; Ricciardi S; Pozzessere D; Ferro A; Proto C; Costanzo R; D'Arcangelo M; Proietto M; Gargiulo P; Di Liello R; Arenare L; De Marinis F; Crinò L; Ciardiello F; Normanno N; Gallo C; Perrone F; Gridelli C; Morabito A J Thorac Oncol; 2022 Sep; 17(9):1086-1097. PubMed ID: 35659580 [TBL] [Abstract][Full Text] [Related]
80. Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320). Otani S; Sasaki J; Nakahara Y; Fukui T; Igawa S; Naoki K; Bessho A; Hosokawa S; Fukamatsu N; Nakamura Y; Kasai T; Sugiyama T; Tokito T; Seki N; Hamada A; Okamoto H; Masuda N Invest New Drugs; 2021 Apr; 39(2):530-536. PubMed ID: 33159674 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]